(19)
(11) EP 3 380 468 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.11.2020 Bulletin 2020/45

(45) Mention of the grant of the patent:
20.05.2020 Bulletin 2020/21

(21) Application number: 16801774.7

(22) Date of filing: 25.11.2016
(51) International Patent Classification (IPC): 
C07D 403/14(2006.01)
A61P 35/00(2006.01)
 A61K 31/501(2006.01)
(86) International application number:
PCT/EP2016/078899
(87) International publication number:
WO 2017/089587 (01.06.2017 Gazette 2017/22)

(54)

BIS-PYRIDAZINE COMPOUNDS AND THEIR USE IN TREATING CANCER

BIS-PYRIDAZIN-VERBINDUNGEN UND DEREN VERWENDUNG IN DER BEHANDLUNG VON KREBS

COMPOSÉS DE BIS-PYRIDAZINE ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 27.11.2015 GB 201520959

(43) Date of publication of application:
03.10.2018 Bulletin 2018/40

(73) Proprietor: Cancer Research Technology Limited
London E20 1JQ (GB)

(72) Inventor:
  • FINLAY, Maurice, Raymond, Verschoyle
    Cambridge Cambridgeshire CB4 0FZ (GB)

(74) Representative: HGF 
1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)


(56) References cited: : 
WO-A1-2015/181539
 WO-A2-2015/101957
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).